Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

Nature Medicine

Volumn 6, Issue 4, 2000, Pages 443-446

  Clynes, Raphael A ^a   Towers, Terri L ^a   Presta, Leonard G ^b   Ravetch, Jeffrey V ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; MONOCLONAL ANTIBODY; RITUXIMAB; TRASTUZUMAB;

ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CANCER MODEL; CANCER TRANSPLANTATION; CYTOTOXICITY; DRUG CYTOTOXICITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOMODULATION; LUNG METASTASIS; MELANOMA; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; IMMUNIZATION, PASSIVE; LYMPHOMA, B-CELL; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, NUDE; RECEPTOR, ERBB-2; RECEPTORS, IGG;

ANIMALIA;

EID: 0034076307     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/74704     Document Type: Article

References (19)

1. Bolland, S. & Ravetch, J.V. Inhibitory pathways triggered by ITIM-containing receptors. Adv. Immunol. 72, 149-177 (1999).
2. Clynes, R.A., Tekechi, Y., Moroi, Y., Houghton, A. & Ravetch, J.V. Fc receptors are required in passive and active immunity to melanoma. Proc. Natl. Acad. Sci. USA 95, 652 (1998).
3. Hudziak, R. et al. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor Mol. Cell Biol. 9, 1165 (1989);
4. Taji, H. et al. Growth inhibition of CD20 positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody. Jpn. J. Cancer Res. 89, 748 (1998).
5. Masui, H., Moroyama, T. & Mendelsohn, J. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes Cancer Res. 46, 5592 (1986);
6. Waldmann, T.A. Lymphokine receptors: a target for immunotherapy of lymphomas. Ann. Oncol. Supp. 13, 5, 1-45 (1994).
7. Tutt, A.L. et al. Monoclonal antibody therapy of a B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors. J. Immunol. 161, 3176 (1998).
8. Pegram, M.D. et al. Phase II study of receptor enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2.neu overexpressing metastatic breast cancer refractory to chemotherapy treatment J. Clin. Oncol. 16, 2659 (1998)
9. Carter, P.L. et al. Humanization of an anti-p185HER2 antibody for human cancer treatment, Proc Natl. Acad. Sci. USA 89, 4285 (1992).
10. Leget, C.A. & Czuczman, M.S. Use of Rituximab, the new FDA-approved antibody. Curr. Opin. Oncol. 10, 548-551 (1998)
11. Kopreski, M., Lipton, A., Harvey, H.A. & Kumar, R. Growth inhibition of breast cancer cell lines by combinations of anti-p185 monoclonal antibody and cytokines. Anticancer Res. 16, 433-436 (1996).
12. Lewis, G.D. et al. Differential responses of human tumor cell lines to antip185HER2 monoclonal antibodies. Cancer Immunol. Immunother. 37, 255-263 (1993).
13. Shan, D., Ledbetter, J.A. & Press, O.W. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 91, 1644-1652 (1998).
14. Takai, T., Li., M., Sylvestre, D., Clynes, R. & Ravetch, J.V. FcR γ chain deletion results in pleiotropic effector cell defects. Cell 76, 519-529 (1994).
15. Takai, T., Ono, M, Hikida, M., Ohmori, H. & Ravetch, J.V. Augmented humoral and anaphylactic responses in Fc_RIIB deficient mice. Nature 379, 346-349 (1996).
16. Funakoshi, S., Longo, D.L. & Murphy, W.J. Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas. J. Immunother. 19, 93-101 (1996).
17. Fan, Z., Masui, H., Altas, I. & Mendelsohn, J. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies Cancer Res. 53, 4322-4328 (1993)
18. Baselga, J., Norton, L., Albanell, J., Kim, Y.M. & Mendelsohn, J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the anti-tumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 58, 2825-2831 (1998).
19. Liu, J., Lester, P., Builder, S.& Shine, J. Characterization of complex formation by humanized anti-1gE monoclonal antibody and monoclonal human IgE. Biochemistry 34, 10474-10482 (1995).